
    
      SARCOVID is an investigator-initiated monocentric randomised proof of concept study that aims
      to evaluate the efficacy and safety of a single dose of sarilumab, in subcutaneous
      administration, in hospitalised patients with moderate to early severe COVID-19 infection,
      compared to the current standard of care.
    
  